An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.

The primary objective of this open-label extension study is to evaluate the long-term **safety** and tolerability of **Tildrakizumab** in adult subjects with active **Psoriatic Arthritis** (PsA). This is clinically relevant as it aims to ensure that the therapeutic benefits of Tildrakizumab are sustained over an extended period without compromising patient safety. Additionally, the study seeks to assess the long-term **efficacy** of Tildrakizumab by evaluating the American College of Rheumatology response criteria, which is crucial for determining the sustained therapeutic impact on disease activity and patient quality of life.

The clinical trial involves a total of **512 participants** diagnosed with **Psoriatic Arthritis**. The study population includes both male and female adults, with an age range that encompasses individuals from young adulthood to middle age. Participants were selected based on their ability to understand the study requirements and their agreement to comply with study protocols, as well as having completed a prior related study without any criteria for premature discontinuation. The trial population includes individuals who are considered vulnerable, indicating a need for careful ethical considerations. Participants' general health status is characterized by active Psoriatic Arthritis, and they have provided informed consent to partake in the study. Lifestyle factors such as diet and physical activity are not specified in the available data.

The clinical trial is designed to evaluate the long-term safety and efficacy of **tildrakizumab** in patients with **psoriatic arthritis**. This is an open-label extension study, which means that both the researchers and participants are aware of the treatment being administered. The trial is categorized as a Phase III study, focusing on assessing the safety and tolerability of the drug, as well as its efficacy based on the American College of Rheumatology response criteria. The primary endpoints include the incidence and intensity of adverse events and achieving ACR 20, ACR 50, and ACR 70 response levels.

Participants will be involved in the study for a maximum treatment period of 108 weeks. The trial is expected to conclude by December 30, 2028. The study begins with an inclusion visit, where participants are screened to ensure they meet the eligibility criteria, such as having completed the parent study treatment period without developing any criteria for premature discontinuation. Follow-up visits will be scheduled to monitor the participants' response to the treatment and to record any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted.

Participants are required to provide written informed consent and agree to comply with study restrictions, scheduled treatments, laboratory assessments, and other procedures. Conditions that may lead to early termination from the study include the development of any criteria for premature discontinuation or withdrawal from the study as outlined in the parent protocol. The study involves the administration of **Ilumetri 100 mg solution for injection in pre-filled syringe** via the subcutaneous route, with a maximum daily dose of 100 mg and a total dose not exceeding 1000 mg over the treatment period.

The clinical trial involves the administration of **Ilumetri**, a pharmaceutical product containing the active substance **tildrakizumab**. Ilumetri is formulated as a **solution for injection** in a pre-filled syringe, specifically designed for subcutaneous administration. Each syringe contains a dosage of 100 mg of tildrakizumab. The maximum daily dose is set at 100 mg, with a total maximum dose of 1000 mg over the course of the treatment period. The treatment is administered over a maximum period of 108 weeks. Tildrakizumab is a protein-based therapeutic agent, classified under the ATC code L04AC17, and is utilized in the management of skin diseases, including **psoriatic arthritis**.

In this open-label extension study, the primary objective is to evaluate the long-term safety and efficacy of tildrakizumab in adult patients with active psoriatic arthritis. The study does not include any non-experimental treatments such as placebo or comparator treatments. Participant compliance with the dosing schedule is monitored throughout the study to ensure adherence to the prescribed regimen. The trial aims to assess the safety and tolerability of the treatment, as well as its efficacy based on the American College of Rheumatology response criteria.

The efficacy of Tildrakizumab in patients with **Psoriatic Arthritis** will be assessed using the American College of Rheumatology (ACR) response criteria. The primary efficacy endpoints include achieving ACR 20, ACR 50, and ACR 70, which represent 20%, 50%, and 70% improvement in tender or swollen joint counts and other relevant clinical measures. These endpoints will be evaluated throughout the study period to determine the long-term efficacy of the treatment. The study is designed as an open-label extension to assess these outcomes in adult subjects who have completed a prior study and continue to meet the inclusion criteria. The efficacy assessments will be conducted in accordance with the study protocol, ensuring that all data collected is consistent and reliable for analysis.